The Health sub-committee of the House Energy & Commerce Committee, set to hold hearings on the re-authorization of the Medical Device User Fee Act in mid-February, CDRH chief Jeffrey Shuren will be called to testify.
A congressional panel is set to hold hearings on the re-authorization of the Medical Device User Fee Act, in what could be a rough outing for FDA officials.
On February 15, the Health sub-committee of the House's Energy & Commerce Committee will call Dr. Jeffrey Shuren, director of the Center for Devices & Radiological Health as its witness. The committee has budget authority over the FDA and CMS.
The GOP-led panel is chaired by Rep. Joe Pitts (R-PA), an outspoken critic of the FDA, who has called the watchdog agency an impediment to continued U.S. leadership in the global medical device field.
"We need the FDA to make sure that devices are safe, but we don't need them to stand in the way of cures or jobs," Pitts wrote in a November, 2011 editorial in The Phildelphia Inquirer. "New inventions and cures will only come if inventors have a clear path to bring their product to market...In recent years, the FDA's approval process has become a bottleneck," he wrote. "It has become less transparent, less predictable, and less efficient."
It was not the first time Pitts set his sights on the regulatory process. In February of last year, he launched an inquiry into why the FDA's medical device approval process takes longer than the European system. And in May, he joined forces with fellow Pennsylvania Rep. Frank Pallone (R) to defend medical imaging spending in a letter to the Medicare Payment Advisory Commission.
The current medical device user fee amendement expires at the end of September.
The FDA asks medical device manufacturers to submit documentation about controls they have in place...
Medical device and pharmaceutical companies paid out $3.5 billion to doctors and hospitals during the...
Endo International agrees to settle as many as 20,000 lawsuits filed in U.S. courts against its...
Acutus Medical secured $26.2 million in new funding for its cardiac mapping technology.